Universal Ibogaine Inc. (IBO.V)
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0400 x N/A |
| Ask | 0.0500 x N/A |
| Day's Range | 0.0500 - 0.0500 |
| 52 Week Range | 0.0400 - 0.2500 |
| Volume | |
| Avg. Volume | 139,099 |
| Market Cap | 9.537M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0310 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- News Direct
Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health Conference
Calgary, AB – TheNewswire - June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO), (OTC:IBOGF) and (FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to transform addiction treat...
- CNW Group
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference
Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022.
- CNW Group
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR
Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.
